Achema middle east

Press Releases

Syntegon delivers strong growth and EBITDA improvements in first half of 2025

Successful growth strategy delivers sales growth in H1 of +11% versus prior year to €824m Strong growth momentum in the Pharma segment EBITDA up +41% to €127m, with margin expanding 300 bps to 15.5%.; all business units contributing ...

Reliable Labeling at Cryogenic Temperatures

In the pharmaceutical cold chain, labels must perform from +8 °C down to –196 °C in liquid nitrogen. At such extremes, conventional adhesives lose tack and ice films hinder adhesion. Melsungen, August 26, 2025 Biopharmaceuticals such as vaccines and advanced therapy...

Er-Kim Announces Exclusive Agreement with CNX Therapeutics to Distribute Oncology Products Across CEE and Turkey

Partnership will broaden portfolio distribution of oncology products to cancer patients in the specified regions Er-Kim, an international pharmaceutical company specializing in the commercialization of novel therapies, today announced a distribution agreement with CNX Therapeutics to supply selected oncology products across Central...

Record international attendance at CPHI & PMEC China 2025 as China in-licensing deals and international partnering increase

China’s biotech sector is now a key driver of innovation across global pipelines, as CPHI Shenzhen prepares for largest ever influx of foreign dealmakers Sino-international trade is accelerating as CPHI & PMEC China (June 24–26, 2025) reported a record-breaking international...

Autopack to host biggest packaging machinery stand at PPMA Total 2025

Leading independent integrator of packaging lines Autopack will showcase a range of cutting-edge automated equipment at PPMA Total 2025, which takes place at Birmingham’s NEC from 23-25 September. The Hereford-based business will take its largest individual stand to date in what...

Friends of Cancer Research and MMS Collaborate to Develop Decision Frameworks for Interim Overall Survival Data in Oncology Trials

MMS, a global, data-focused clinical research organization (CRO), announced today that it has been chosen by Friends of Cancer Research (Friends), a leading nonprofit dedicated to accelerating innovation in cancer research, to support the development of practical decision frameworks...

PADCEV™ Plus KEYTRUDA™ Significantly Improves Survival for Certain Patients with Bladder Cancer When Given Before and After Surgery

PADCEV plus KEYTRUDA is the first and only regimen to improve survival when used before and after standard of care (surgical cystectomy) in cisplatin-ineligible patients with muscle-invasive bladder cancer Results will be discussed with global health authorities for...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Must read

Translate »